• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PIs Need to Take a Look at Their Recruitment Mindset, Survey Shows

PIs Need to Take a Look at Their Recruitment Mindset, Survey Shows

February 21, 2022

Principal investigators (PIs) frequently assume patients are unable or unwilling to take part in a clinical trial, limiting enrollment efforts, according to ZS’ 2021 U.S. Voice of Site/Voice of Patient survey.

The survey, which questioned 200 patients (including 83 who came from underrepresented populations), found that PIs greatly underestimate patient willingness to participate in trials.

Of the patients PIs assumed to be eligible for trials, 56 percent were not in fact offered the opportunity, while 55 percent of patients offered the chance to join a trial were expected to say no, according to the PIs who participated in the survey.

The top reasons PIs did not mention clinical trials to patients were: concerns about patient compliance with scheduled assessments based on their history of physician visits; patients being well-managed on their current treatment(s); concerns about drug regimen compliance based on history of treatment adherence in the past; concerns about patients being able to reliably make it to the site; and belief that patients don’t have the health literacy or understanding needed to grasp what’s required for informed participation.

Of the patient respondents, which were a combination of those with trial experience and those who had never participated, a majority — 75 percent — said they would likely consider a clinical trial if a doctor recommended it. This was also the case for 77 percent of underrepresented patients.

In addition, the survey revealed that sites say that recruitment and referral, training and contract negotiations are the most important areas for sponsors to improve upon.

Of the more than 150 principal investigators and nearly 80 research coordinators that responded, nearly half (48 percent) believe that patient recruitment and referral require the most support from sponsors, making this the number one trial element in need of improvement.

Enrollment is frequently a struggle area for sites, and 50 percent of sites will enroll no more than a single patient, with many enrolling none at all, according to Sharon Karlsberg, principal at ZS, a consulting firm that specializes in clinical trial research.

Coming in second on areas needing improvement, 46 percent of PIs and coordinators named training and other learning opportunities, while negotiating and signing contracts with sponsors came in third, with 45 percent of the respondents citing it as an area in need of improvement.

Access ZS’ survey presentation here: https://bit.ly/3hbpjxj.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing